The role of sublingual sufentanil nanotabs for pain relief

Harold S. Minkowitz; Keith Candiotti

doi:10.1517/17425247.2015.975202

The role of sublingual sufentanil nanotabs for pain relief

Harold S. Minkowitz, Keith Candiotti

Anesthesiology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Introduction: The authors discuss a novel patient controlled analgesia system utilizing a preprogrammed device that delivers a small submucosal tablet of sufentanil.Areas covered: This submucosal sufentanil system is not yet commercially available. A literature review of the current patient controlled analgesia systems and current information of this device are discussed.Expert opinion: This novel device has the potential to enhance patient safety as it is preprogrammed and delivers a standard dose of sufentanil, a rapidly acting opioid devoid of active metabolites.

Original language	English (US)
Pages (from-to)	845-851
Number of pages	7
Journal	Expert Opinion on Drug Delivery
Volume	12
Issue number	5
DOIs	https://doi.org/10.1517/17425247.2015.975202
State	Published - May 1 2015

Keywords

Microtablet
Pain
Sublingual
Sufentanil

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1517/17425247.2015.975202

Cite this

@article{558946a4600f4376a7fc6c43e6f4eb54,

title = "The role of sublingual sufentanil nanotabs for pain relief",

abstract = "Introduction: The authors discuss a novel patient controlled analgesia system utilizing a preprogrammed device that delivers a small submucosal tablet of sufentanil.Areas covered: This submucosal sufentanil system is not yet commercially available. A literature review of the current patient controlled analgesia systems and current information of this device are discussed.Expert opinion: This novel device has the potential to enhance patient safety as it is preprogrammed and delivers a standard dose of sufentanil, a rapidly acting opioid devoid of active metabolites.",

keywords = "Microtablet, Pain, Sublingual, Sufentanil",

author = "Minkowitz, {Harold S.} and Keith Candiotti",

note = "Funding Information: HS Minkowitz has received research funding from AcelRx, Incline Pharma and The Medicines Co. He is a consultant for AcelRx and The Medicines Co. and has received honoraria from Acel RX. K Candiotti has been part of a clinical investigation sponsored by AcelRx. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2015 Informa UK, Ltd.",

year = "2015",

month = may,

day = "1",

doi = "10.1517/17425247.2015.975202",

language = "English (US)",

volume = "12",

pages = "845--851",

journal = "Expert Opinion on Drug Delivery",

issn = "1742-5247",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - The role of sublingual sufentanil nanotabs for pain relief

AU - Minkowitz, Harold S.

AU - Candiotti, Keith

N1 - Funding Information: HS Minkowitz has received research funding from AcelRx, Incline Pharma and The Medicines Co. He is a consultant for AcelRx and The Medicines Co. and has received honoraria from Acel RX. K Candiotti has been part of a clinical investigation sponsored by AcelRx. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2015 Informa UK, Ltd.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Introduction: The authors discuss a novel patient controlled analgesia system utilizing a preprogrammed device that delivers a small submucosal tablet of sufentanil.Areas covered: This submucosal sufentanil system is not yet commercially available. A literature review of the current patient controlled analgesia systems and current information of this device are discussed.Expert opinion: This novel device has the potential to enhance patient safety as it is preprogrammed and delivers a standard dose of sufentanil, a rapidly acting opioid devoid of active metabolites.

AB - Introduction: The authors discuss a novel patient controlled analgesia system utilizing a preprogrammed device that delivers a small submucosal tablet of sufentanil.Areas covered: This submucosal sufentanil system is not yet commercially available. A literature review of the current patient controlled analgesia systems and current information of this device are discussed.Expert opinion: This novel device has the potential to enhance patient safety as it is preprogrammed and delivers a standard dose of sufentanil, a rapidly acting opioid devoid of active metabolites.

KW - Microtablet

KW - Pain

KW - Sublingual

KW - Sufentanil

UR - http://www.scopus.com/inward/record.url?scp=84928329654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928329654&partnerID=8YFLogxK

U2 - 10.1517/17425247.2015.975202

DO - 10.1517/17425247.2015.975202

M3 - Article

C2 - 25388859

AN - SCOPUS:84928329654

VL - 12

SP - 845

EP - 851

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 5

ER -

The role of sublingual sufentanil nanotabs for pain relief

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this